Previous 10 | Next 10 |
home / stock / dyn / dyn articles
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results ...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Shares of Franklin Covey Co. (NYSE: FC...
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial res...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday. The Dow traded up 0.55% to...
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) r...
U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 50 points on Thursday. Shares of Cal-Maine Foods, Inc. (NAS...
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focuse...